click below
click below
Normal Size Small Size show me how
NMSUPharmacology
Effector
| Question | Answer |
|---|---|
| Muscarinic Agonist | Bladder GI smooth muscle |
| Muscarinic Antagonist | prevents receptor activation by ACH |
| Cholinesterase Inhibitors | Optimal dosage is indicated by "increasd ability to raise eyelids" |
| Neuromuscular Blocking Agents | eyelids and muscles of mastication effected first; affect ACH at nicitonic-m receptors |
| Adrenergic agonists (catecholamines and noncatecholamines) | alpha-1 and beta-1 activations; uterine muscles |
| Adrenergic Antagonists, Beta Blockade | blocks beta 1 and 2 receptors |
| Indirect-Acting Antiadrenergic Agents | depletion of norepi from postganglionic sypmathetic neuron synthesis |
| Dopaminergic agents | promotion of dopamine synthesis, prevention of dopamine degradation, promotion of dopamine release, direct activionat of dopamine receptors |
| Anticholinergic Agents | prevent activation of cholinergic receptors, blockade of muscarinic cholinergic receptors in the striatum |
| Anticonvulsant/antiepileptic | suppression of Na and Ca influx, potentiation of GABA |